

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3  
4  
5  
6  
7 **An aptamer-functionalized gold nanoparticle biosensor for the**  
8  
9  
10 **detection of prion protein**  
11

12  
13 Hai-Jie Zhang<sup>a,b</sup>, Yi-Hui Lu<sup>a</sup>, Yi-Juan Long<sup>a</sup>, Qin-Long Wang<sup>a</sup>, Xiao-Xiao Huang<sup>a</sup>,  
14  
15 Rui Zhu<sup>a</sup>, Xi-Liang Wang<sup>a</sup>, Li-Ping Liang<sup>a</sup>, Ping Teng<sup>a</sup>, Hu-Zhi Zheng<sup>a\*</sup>  
16  
17

18  
19  
20  
21 <sup>a</sup> College of Chemistry and Chemical Engineering, Southwest University,  
22  
23 Chongqing 400715, P. R. China. Email: zhenghz@swu.edu.cn.  
24  
25

26  
27 <sup>b</sup> Environmental Monitoring Station of Dazhou, Dazhou, Sichuan, 635000, P. R.  
28  
29 China  
30  
31

32  
33  
34 **Abstract** Prions are a special class of pathogens that cause a number of  
35  
36 fatal neurodegenerative diseases in mammals. This paper presents a very simple  
37  
38 and convenient biosensor for detecting prion protein, in which a prion protein  
39  
40 aptamer was used as the molecular recognition group and gold nanoparticles  
41  
42 were used as the signal report group. Binding of the target molecular prion  
43  
44 protein resulted in the enhancement of resonance light scattering (RLS) by the  
45  
46 gold nanoparticles. A linear relationship was then identified between the  
47  
48 enhanced RLS intensity and the concentration of prion protein in the range 0.2  
49  
50 to 50 nmol/L, with a limit of detection of 0.07 nmol/L ( $3\sigma$ ). The biosensor has  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

\* Corresponding author. E-mail address: zhenghz@swu.edu.cn (H. Zheng).

1  
2  
3  
4 very good selectivity for prion protein without interference by coexisting  
5  
6 proteins, amino acids or metal ions. This “aptasensor” offers a rapid, selective  
7  
8 and sensitive route for prion protein detection and has good potential for use in  
9  
10 practical applications.  
11  
12  
13  
14  
15  
16  
17  
18

## 19 **1. Introduction**

20  
21  
22 Prion diseases, also known as transmissible spongiform encephalopathies (TSEs),  
23  
24 are a group of fatal neurodegenerative disorders that affect humans and animals. The  
25  
26 transformation of host-encoded normal prion protein (PrP<sup>C</sup>) to the pathological  
27  
28 conformer (PrP<sup>Sc</sup>) and the subsequent aggregation of PrP<sup>Sc</sup> may cause  
29  
30 Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia in humans,  
31  
32 bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and other prion  
33  
34 diseases<sup>1</sup>. PrP<sup>C</sup> and PrP<sup>Sc</sup> have the same amino acid sequence but are different in  
35  
36 conformation, whereby PrP<sup>C</sup> has a high content of alpha-helices and PrP<sup>Sc</sup> is rich in the  
37  
38 beta-sheet structure<sup>2</sup>. Affecting approximately one in every million people, these rare  
39  
40 disorders may arise either spontaneously, via inheritance of a predisposing mutation, or  
41  
42 through infection. Acquisition of disease by the latter mechanism has drawn intense  
43  
44 interest among scientists and the general public, especially in light of the recent  
45  
46 outbreak of BSE in the United Kingdom<sup>3</sup> and the appearance of a new variant of  
47  
48 Creutzfeldt-Jakob disease (vCJD)<sup>4,5</sup>. Currently, several methods for the detection of  
49  
50 prions have been established, including protein misfolding cyclic amplification (PMCA)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4<sup>6</sup>, the conformation-dependent assay<sup>7</sup>, and a combination of new ligands<sup>8, 9</sup> with  
5  
6  
7 spectroscopic techniques<sup>10</sup>. For example, Soto and co-workers<sup>11</sup> detected prions by  
8  
9 cyclic amplification of protein misfolding. MacGregor and co-workers<sup>12</sup> detected PrP<sup>Sc</sup>  
10  
11 in the blood using the time-resolved fluoro-immunoassay. These two methods were  
12  
13 sensitive and based on immunoassays but both require complicated functionalization  
14  
15 steps and expensive equipment. Therefore, developing a convenient and sensitive assay  
16  
17 protocol is of great importance.  
18  
19  
20  
21

22  
23 Recently, the resonance light scattering (RLS) technique, which has the distinct  
24  
25 advantages of simplicity, rapidness and high sensitivity, was developed to study the  
26  
27 extended aggregates of chromophores or bio-assemblies<sup>13, 14</sup>. The RLS technique has  
28  
29 been proposed for the determination of DNA<sup>15</sup>, proteins<sup>16</sup>, metal ions<sup>17</sup>, and  
30  
31 saccharides<sup>18</sup>, amongst other compounds. Metal nanoparticles, because of their  
32  
33 extremely strong light scattering at plasma-resonance wavelengths, have been used as  
34  
35 RLS probes, enabled by the rapid development of nanotechnology<sup>19-20</sup>. For example,  
36  
37 Li and co-workers<sup>21</sup> reported a sensitive light scattering assay for lysozyme using gold  
38  
39 nanoparticles (AuNPs) as a probe. Binding studies between an aptamer and its target  
40  
41 is a new strategy applied in molecular recognition chemistry<sup>22</sup>. Therefore, an aptamer  
42  
43 that can specifically bind to prion protein with high affinity may be a useful new  
44  
45 ligand for the detection of PrP. The selection of DNA aptamers against PrP has been  
46  
47 reported<sup>23, 24</sup>. Xiao and co-workers<sup>25</sup> used aptamer-modified quantum dots and  
48  
49 magnetic microparticles in a sandwich structure to detect prion protein, but their assay  
50  
51 process was complex. In the present work, we use a simple biosensor to detect prion  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 protein, in which a prion protein aptamer is used as a molecular recognition group and  
5  
6 AuNPs are used as a signal report group. The biosensor shows high selectivity and  
7  
8 sensitivity.  
9

## 10 11 12 13 **2. Material and methods**

### 14 15 16 17 **2.1 Reagents**

18  
19 Chloroauric acid and chymotrypsin were purchased from Aladdin Reagent Co.,  
20  
21 Ltd (Shanghai, China). Sodium citrate was purchased from Beijing Chemical Works  
22  
23 (Beijing, China). Lysozyme from chicken egg white (activity  $\geq 40,000$  units/mg),  
24  
25 human serum albumin (HSA), horseradish peroxidase (HRP), and glucose oxidase  
26  
27 (GOD) were purchased from Sigma-Aldrich (St. Louis, MO). All reagents used for  
28  
29 purification of rPrP were purchased from Genview (Tianjin, China). L-Glycine (Gly),  
30  
31 L-tyrosine (Tyr), L-methionine (Met), L-phenylalanine (Phe), L-alanine (Ala),  
32  
33 L-histidine (His), L-arginine (Arg), L-Lysine (Lys), L-glutamic acid (Glu), L-aspartate  
34  
35 (Asp), L-leucine (Leu), L-isoleucine (Ile), and L-valine (Val) were purchased from  
36  
37 Beijing Dingguo Changsheng Biotechnology Co., Ltd (Beijing, China). Bovine serum  
38  
39 albumin (BSA) was purchased from Shanghai BioLife Science & Technology Co.,  
40  
41 Ltd (Shanghai, China). Pepsin was purchased from Shanghai Institute of Biological  
42  
43 Products (Shanghai, China). Cellulase was purchased from Dongfeng Biochemistry  
44  
45 Technology Co., Ltd (Shanghai Institute of Biological Science, China). Thrombin was  
46  
47 purchased from Heilongjiang Dilong Pharmaceutical Co., Ltd (Suihua, China).  
48  
49 Glusulase and thiol aptamer (5'-SH-(C6)-CTT ACG GCG GGG CAA TT-3') were  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 purchased from Sangon Biotech Co., Ltd (Shanghai, China). Human serum samples  
5  
6 were obtained from Southwest University Hospital (Chongqing, China). All solutions  
7  
8 were prepared with Milli-Q ultrapure water.  
9  
10

## 11 12 13 **2.2 Apparatus** 14

15  
16 The dynamic light scattering (DLS) signal of aptamer-functionalized AuNPs  
17  
18 (APT-AuNPs) was recorded by a Zetasizer Nano ZS90 apparatus (Malvern  
19  
20 Instruments Ltd, Malvern, UK). The morphology and dispersivity of APT-AuNPs  
21  
22 were measured by a Tecnai G2 F20 S-TWIN field emission transmission electron  
23  
24 microscope (TEM) (FEI, Hillsboro, OR). The absorption spectra were recorded by a  
25  
26 UV-2450 spectrophotometer (Shimadzu, Kyoto, Japan). An F-4500 fluorescence  
27  
28 spectrometer (Hitachi, Japan) was used to record the RLS spectra in synchronous  
29  
30 scanning mode ( $\text{ex} - \text{em} = 0$ ). Both excitation and emission slit widths were kept at 10  
31  
32 nm and the RLS intensity was recorded at 560 nm.  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **2.3 Preparation and functionalization of AuNPs** 42

43  
44 AuNPs (13 nm) were synthesized by citrate reduction of  $\text{HAuCl}_4^{26}$  and  
45  
46 functionalized with the thiol aptamer<sup>27-29</sup>. Briefly, 5 mL of AuNPs was mixed with 3  
47  
48 OD thiol aptamer at room temperature. The final oligonucleotide concentration was  
49  
50 3.6  $\mu\text{mol/L}$ . The mixture was incubated for 16 h at room temperature and, after  
51  
52 adjusting the solution to 0.1 mol/L NaCl, it was further incubated for 40 h at room  
53  
54 temperature. It was then centrifugated at 10,000 rpm using a LRH-250-Z Z383K  
55  
56 high-speed bench centrifuge (Hermle Labortechnik GmbH, Wehingen, Germany) for  
57  
58  
59  
60

1  
2  
3  
4 1 h. The collected pellet was re-dispersed with ultrapure water, followed by addition of  
5  
6 0.3 mol/L NaCl, 10 mmol/L phosphate buffered saline (PBS) and 5 mmol/L EDTA.  
7  
8

#### 9 10 **2.4 Purification of recombinant human prion protein (rPrP)** 11

12  
13 The rPrP (23-231) was expressed in *Escherichia coli* BL21 (DE3)<sup>30</sup> and  
14 purified using a nickel ion-charged Sepharose column, as previously described<sup>31</sup>.  
15  
16 Protein concentration was determined using a Bio-Rad (Hercules, CA) protein  
17 assay kit.  
18  
19  
20  
21  
22  
23  
24

#### 25 **2.5. Assays of rPrP** 26

27  
28 A solution of APT-AuNPs (1.0 nmol/L) was mixed with 80  $\mu$ L of PBS (pH 6.0,  
29 0.2 mol/L) and 80  $\mu$ L of 2 mol/L NaCl at room temperature. A given volume of rPrP  
30 solution was then added to the mixture, and ultrapure water was added to bring the  
31 total volume to 0.80 mL. After incubating for 30 min at room temperature, the RLS  
32 spectra were recorded and the RLS intensity at 560 nm was used for quantitative  
33 analysis.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43


#### 44 **2.6 Analysis of rPrP in a human serum sample** 45

46  
47 To test the performance of our method in complex samples, rPrP in human  
48 serum was detected. A series of mixtures (0.80 mL) of 10-fold diluted human  
49 serum sample and APT-AuNPs (1.0 nmol/L) were spiked with rPrP (0–10  
50 nmol/L). After equilibration at room temperature for 30 min, their RLS spectra  
51 were recorded by an F-4500 fluorescence spectrometer.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 3. Results and discussion

#### 3.1 rPrP enhance the RLS of APT-AuNPs

After modification with aptamer, a slight shift in the surface plasma resonance band of AuNPs from 520 to 523 nm was observed (Fig. S1). And the absorbance of APT-AuNPs reduced after the addition of rPrP (Fig. S2). APT-AuNPs exhibited a wide RLS peak near 520 nm. However, after the addition of rPrP to the APT-AuNPs solution, an obvious enhancement of the RLS signal near 560 nm could be observed (Fig. S3).




**Fig. 1** TEM images of APT-AuNPs in the absence (A) and presence of 20 nmol/L (B) and 50 nmol/L rPrP (C). Concentration of APT-AuNPs and NaCl are 1.0 nmol/L and 0.20 mol/L, respectively. The pH value is adjusted to 6.0 with PBS.

TEM was used to explain the red-shift and enhancement of RLS spectra. As shown in Fig. 1A, APT-AuNPs were well-dispersed in PBS at pH 6.0 containing 0.2 mol/L of NaCl. However, APT-AuNPs aggregated in the presence of 20



nmol/L rPrP (Fig.1B) and 50 nmol/L rPrP (Fig.1C). DLS results also confirmed the rPrP-induced aggregation of APT-AuNPs (Fig. S4). According to Pasternack and Collings<sup>32</sup>, RLS is sensitive to aggregation and size changes so the aggregation of AuNPs enhanced the intensity of RLS near 560 nm.

### 3.2 Selectivity of APT-AuNPs



**Fig. 2** Selectivity of rPrP detection (rPrP, 20 nmol/L; APT-AuNPs 1.0 nmol/L) with the following interference: (A) metal ions ( $\text{Cd}^{2+}$ ,  $\text{Cu}^{2+}$ : 20  $\mu\text{mol/L}$ ;  $\text{Pb}^{2+}$ ,  $\text{Al}^{3+}$ ,  $\text{Co}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Ni}^{2+}$ ,  $\text{Fe}^{2+}$ : 10  $\mu\text{mol/L}$ ;  $\text{Ca}^{2+}$ : 8  $\mu\text{mol/L}$ ,  $\text{Hg}^{2+}$ : 4  $\mu\text{mol/L}$ ;  $\text{Mg}^{2+}$ : 2  $\mu\text{mol/L}$ ;  $\text{K}^+$ ,  $\text{Cr}^{3+}$ : 0.2  $\mu\text{mol/L}$ ;  $\text{Ag}^+$ : 0.1  $\mu\text{mol/L}$ ); (B) amino acids (Met, Arg, Tyr, Ala, Gly, Glu, Ile, Asp, His: 20  $\mu\text{mol/L}$ ; Val, Phe: 8  $\mu\text{mol/L}$ ; Lys, Leu: 4  $\mu\text{mol/L}$ ); and (C) proteins (BSA, lysozyme: 2  $\mu\text{mol/L}$ ; thrombin, pepsin, GOD: 0.2  $\mu\text{mol/L}$ ; HRP: 0.4  $\mu\text{mol/L}$ ; cellulase: 0.04  $\mu\text{mol/L}$ ; HSA, glucosylase: 0.02  $\mu\text{mol/L}$ , chymotrypsin: 0.16  $\mu\text{mol/L}$ ).  $I_0$  is the RLS intensity at 560 nm of the APT-AuNPs solution in the absence of rPrP.  $I$  represent the RLS intensity of the APT-AuNPs in the presence of amino acids, proteins, metal ions, or rPrP.


To test the specificity of this assay towards rPrP, we mixed rPrP or potentially interfering metal ions, amino acids, and proteins individually with 1.0

1  
2  
3  
4 nmol/L of APT-AuNPs. We tested 14 species of metal ions, 13 amino acids and  
5  
6  
7 10 types of proteins with concentrations that are similar to the physiological  
8  
9 environment; none of these caused any change in RLS intensity (Fig. 2). These  
10  
11 results confirm that a prion protein aptamer can function as a molecular  
12  
13 recognition group that can specifically combine with rPrP and, importantly, that  
14  
15 only rPrP can increase the RLS intensity of APT-AuNPs.  
16  
17  
18

19  
20 The isoelectric point (pI) of rPrP is about 10.0. Under the present  
21  
22 experimental condition (pH 6.0), rPrP is positively charged and APT-AuNPs are  
23  
24 negatively charged, so it is possible that non-specific, electrostatic interactions  
25  
26 may occur. However, positively charged amino acids such as Arg (20  $\mu\text{mol/L}$ ),  
27  
28 His (20  $\mu\text{mol/L}$ ), Lys (4  $\mu\text{mol/L}$ ) and other positively charged proteins such as  
29  
30 chymotrypsin (0.16  $\mu\text{mol/L}$ ) had no effect on the RLS signal of the system. The  
31  
32 amyloidogenic protein lysozyme (2  $\mu\text{mol/L}$ ) and most metal ions ( $> 0.1 \mu\text{mol/L}$ )  
33  
34 also failed to affect the RLS signal.  
35  
36  
37  
38  
39  
40

41  
42 This high specificity is thus apparently due to highly specific binding  
43  
44 between the aptamer and the related substrate, i.e., rPrP. Scheme 1 illustrates the  
45  
46 mechanism behind the enhancement in the RLS signal caused by rPrP. The  
47  
48 aptamer used in this work can bind with the 23-90 epitope of PrP<sup>23</sup>. After  
49  
50 functionalized with aptamer, the AuNPs were very stable because of protection  
51  
52 by the aptamer. In the presence of rPrP, the APT-AuNPs reacted under the  
53  
54 chosen conditions specifically with rPrP to form an AuNPs-aptamer-rPrP  
55  
56 complex. The large surface area of the Apt-AuNPs provided a suitable binding  
57  
58  
59  
60


1  
2  
3  
4 site for rPrP, which increases local protein concentrations and promotes  
5  
6 oligomer formation on the AuNPs surfaces<sup>33,34</sup>. Oligomer formation could then  
7  
8 lead to aggregation of rPrP. The specific binding between rPrP and Apt-AuNPs  
9  
10 then resulted in further binding of the Apt-AuNPs onto the surfaces of the rPrP  
11  
12 aggregates. This process continued and finally formed large aggregates (Scheme  
13  
14  
15  
16  
17 1). Additionally, in the presence of NaCl, the aggregation of AuNPs enhanced,  
18  
19 and a strong RLS intensity was observed<sup>35</sup>.



35  
36 **Scheme 1.** Interactions between APT-AuNPs and rPrP.  
37  
38  
39  
40  
41

### 42 3.3 Optimization of the assay conditions

43  
44  
45 The RLS detection conditions were optimized to develop a sensitive, simple  
46  
47 and practical assay for rPrP. The effects of pH, NaCl concentration, APT-AuNPs  
48  
49 concentration, and reaction time are shown in Fig. 3.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fig. 3** Optimization of the assay conditions. A: pH (APT-AuNPs, 1.0 nmol/L; rPrP, 20 nmol/L); B: APT-AuNPs concentration (pH 6.0 PBS, 20 mmol/L; rPrP, 20 nmol/L); C: NaCl concentration (APT-AuNPs, 1.0 nmol/L; rPrP, 20 nmol/L; pH 6.0 PBS, 20 mmol/L); D: Reaction time (APT-AuNPs, 1.0 nmol/L; rPrP, 20 nmol/L; pH 6.0 PBS, 20 mmol/L).  $I_0$  is the RLS intensity at 560 nm of the APT-AuNPs solution in the absence of rPrP.  $I$  represent the RLS intensity of the APT-AuNPs in the presence of rPrP.

As can be seen in Fig. 3A, the relative intensity of the RLS signal was the highest at pH 6.0. Thus, pH 6.0 PBS buffer solution was selected.

The effect of APT-AuNPs concentration on the RLS signal was studied, as seen in Fig. 3B. Considering both the sensitivity of the assay and the desire to

1  
2  
3  
4 minimize reagent consumption, the best concentration of APT-AuNPs was 1.0  
5  
6 nmol/L.  
7


8  
9 NaCl plays an important role in achieving high sensitivity in this assay by  
10  
11 inducing aggregation of the AuNPs. The influence of NaCl concentration is shown in  
12  
13 Fig. 3C. The relative intensity of the RLS signal reached a maximum at 2.0 mol/L  
14  
15 NaCl. However, APT-AuNPs became unstable above 0.2 mol/L NaCl, so 0.2 mol/L of  
16  
17 NaCl was chosen for subsequent use.  
18  
19  
20  
21

22  
23 The reaction time was investigated, as shown in Fig. 3D. There was no  
24  
25 obvious change in relative RLS intensity over 1 h, so we chose 30 min as a  
26  
27 standard reaction time.  
28  
29

### 30 31 **3.4 Quantitative detection of rPrP**

32  
33  
34 Mixing APT-AuNPs with rPrP resulted in the appearance of an RLS band around  
35  
36 560 nm. The RLS signal increased linearly with increasing rPrP concentration. Under  
37  
38 the optimized conditions, the RLS intensity at 560 nm exhibited a linear relationship  
39  
40 with the concentration of rPrP from 0.2–50 nmol/L. The linear regression equation  
41  
42 was  $I_{\text{RLS}} = 17.892 C + 103.6$  ( $R^2 = 0.9918$ ) (Fig. 4), where  $I_{\text{RLS}}$  is the RLS intensity of  
43  
44 APT-AuNPs at 560 nm and  $C$  is the concentration of rPrP. The detection limit was  
45  
46 0.07 nmol/L ( $3\sigma$ ), and the relative standard deviation was 1.4% ( $n=11$ ) for 20 nmol/L  
47  
48 rPrP. Compared with immunological methods<sup>36</sup>, which are currently the most  
49  
50 important methods for the detection of prion, our method is simpler and more  
51  
52 convenient. Our method has a higher sensitivity than the fluorescence spectroscopy  
53  
54 assay<sup>37</sup>, and the selectivity of this assay is higher and was enhanced several times  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 compared with our previous results<sup>38</sup>.  
5  
6  
7



24 **Fig. 4** Linear plot of the RLS intensity=against the rPrP concentration at pH 6.0  
25 PBS in the presence of 0.2 mol/L NaCl. Concentration of rPrP: 0, 0.2, 0.5, 1.0,  
26 2.0, 5.0, 10, 20, 50 nmol/L.  $I_{RLS}$  is the RLS intensity at 560 nm of the  
27 APT-AuNPs solution with different concentrations of rPrP.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37


### 38 3.5 Interference from coexisting substances

39  
40

41 The APT-AuNPs biosensor was highly selective for rPrP detection. In  
42 biological samples, such as human serum, there are many coexisting metal ions,  
43 amino acids, and proteins that potentially interfere with the detection of rPrP. A  
44 number of coexisting substances (Table S1) were studied for potential  
45 interference. In the presence of these substances, a relative error of less than  $\pm 5$   
46 % was considered to be acceptable. Most of the amino acids, proteins and metal  
47 ions tested did not affect the determination. For example, in human serum, most  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

amino acids are present at concentrations below 0.50 mmol/L and after spiking the reaction system with serum, dilution was able to eliminate interference.

### 3.6 Detection of rPrP in human serum



**Fig. 5** Detection of rPrP spiked in a solution of human serum in pH 6.0 PBS.  $I$  is the RLS intensity at 560 nm of the APT-AuNPs solution after adding human serum spiked with standard solutions of purified rPrP and  $I_0$  is the RLS intensity at 560 nm of APT-AuNPs solution in the presence of human serum without purified rPrP. The concentration of APT-AuNPs was 1.0 nmol/L.

Purified rPrP (0-10 nmol/L) was spiked into diluted human serum. The calibration curve ( $(I-I_0)/I_0 = 0.0003 + 0.1246C$ ,  $R^2=0.9914$ ) (Fig.5) was used to measure an unknown concentration of rPrP in the presence of 0.2 mol/L NaCl. The concentration of rPrP in the human serum sample was calculated to be 2.1 nmol/L, while the concentration of prion protein in plasma is less than 9 ng/mL<sup>39</sup>. Thus, the “aptasensor” offers a rapid, highly selective and sensitive route for rPrP detection and has high potential for practical applications.

#### 4. Conclusion

In this work, APT-AuNPs aggregated to form large particles after reaction with rPrP and showed incremental increases in RLS intensity with increasing rPrP concentration. Thus, the aptamer-based RLS method was developed to detect rPrP with high sensitivity and selectivity. This assay was successfully applied to the detection of rPrP in a serum sample. Compared with immunological methods and the fluorescence spectroscopy assay, our method offers a simple, selective and sensitive route for prion protein detection and provides high potential for practical applications.

#### Acknowledgements

This research was supported by grants from the National Basic Research Program of China (Grant No. 2011CB933600), National Natural Science Foundation of China (No. 21175110), the Fundamental Research Funds for the Central Universities (No. XDJK2012C048), and the Research Fund for the Doctor Program of Southwest University (SWU112071).

#### Notes and references

<sup>a</sup> College of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, P. R. China. Email: zhenghz@swu.edu.cn.

<sup>b</sup> Environmental Monitoring Station of Dazhou, Dazhou, Sichuan, 635000, P. R. China



1  
2  
3  
4 Electronic Supplementary Information (ESI) available: [The following material is  
5  
6 available free of charge: Normalized UV-Vis spectra of AuNPs and APT-AuNPs  
7  
8 (Fig. S1); UV-vis absorbance spectra of APT-AuNPs in the absence and presence  
9  
10 of 20 nmol/L rPrP (Fig. S2); The RLS spectra of APT-AuNPs in the absence and  
11  
12 presence of rPrP (Fig. S3); Hydrodynamic diameter of APT-AuNPs in the absence  
13  
14 and presence of rPrP in pH 6.0 PBS (Fig. S4); Effect of coexisting substances on  
15  
16 the determination of rPrP using the APT-AuNPs system containing 0.2 mol/L NaCl  
17  
18 (Table S1).]. See DOI: 10.1039/b000000x/  
19  
20  
21  
22  
23  
24

- 25 1 S. B. Prusiner, *Science*, 1991, **252**, 1515.
- 26  
27 2 W. Q. Zou, J. Zheng, D. M. Gray, P. Gambetti, S. G. Chen, *Proc. Natl. Acad.*  
28  
29 *Sci. U.S.A.*, 2004, **101**, 1380.
- 30  
31 3 G. A. Wells, J. W. Wilesmith, *Brain Pathol.*, 1995, **5**, 91.
- 32  
33 4 S. B. Prusiner, *Proc. Natl. Acad. Sci. U.S.A.*, 1998, **95**, 13363.
- 34  
35 5 J. Collinge, *Annu. Rev. Neurosci*, 2001, **24**, 519.
- 36  
37 6 P. C. Klohn, L. Stoltze, E. Flechsig, M. Enari, C. Weissmann, *Proc. Natl. Acad.*  
38  
39 *Sci. U.S.A.*, 2003, **100**, 11666.
- 40  
41 7 A. M. Thackray, L. Hopkins, M. A. Klein, R. Bujdoso, *J. Virol.*, 2007, **81**,  
42  
43 12119.
- 44  
45 8 J. A. Kornblatt, S. Marchal, H. Rezaei, M. J. Kornblatt, C. Balny, *Cell. Mol.*  
46  
47 *Biol.*, 2004, **50**, 387.
- 48  
49 9 C. Negrodo, E. Monks, T. Sweeney, *BMC Biotechnol.*, 2007, **7**, 1.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


- 1  
2  
3  
4 10 F. Fujii, M. Horiuchi, M. Ueno, H. Sakata, I. Nagao, M. Tamura, M. Kinjo,  
5  
6  
7 *Anal. Biochem.*, 2007, **370**, 131.  
8
- 9  
10 11 C. Soto, L. Anderes, S. Suardi, F. Cardone, J. Castilla, M. J. Frossard, S. Peano,  
11  
12 P. Saa, L. Limido, M. Carbonatto, J. Ironside, J. M. Torres, M. Pocchiari, F.  
13  
14 Tagliavini, *FEBS Lett.*, 2005, **579**, 638.  
15
- 16  
17 12 I. MacGregor, J. Hope, G. Barnard, L. Kirby, O. Drummond, D. Pepper, V.  
18  
19 Hornsey, R. Barclay, H. Bessos, M. Turner, C. Prowse, *Vox Sang*, 1999, **77**, 88.  
20
- 21  
22 13 C. Z. Huang, C. X. Yang, Y. F. Li, *Anal. Lett.*, 2003, **36**, 1557.  
23
- 24  
25 14 K. Kano, K. Fukuda, H. Wakami, R. Nishiyabu, R. F. Pasternack, *J. Am. Chem.*  
26  
27 *Soc.*, 2000, **122**, 7494.  
28
- 29  
30 15 P. Bao, A. G. Frutos, C. Greef, J. Lahiri, *Anal. Chem.*, 2002, **74**, 1792.  
31
- 32  
33 16 H. Zhong, J. J. Xu, H. Y. Chen, *Talanta*, 2005, **67**, 749.  
34
- 35  
36 17 Z. L. Jiang, G. Q. Wen, Y. Y. Fan, C. N. Jiang, Q. Y. Liu, Z. Huang, A. H.  
37  
38 Liang, *Talanta*, 2010, **80**, 1287.  
39
- 40  
41 18 L. Shang, H. J. Chen, L. Deng, S. J. Dong, *Biosens. Bioelectron.*, 2008, **23**,  
42  
43 1180.  
44
- 45  
46 19 B. A. Du, Z. P. Li, C. H. Liu, *Angew. Chem. Int. Ed.*, 2006, **45**, 8022.  
47
- 48  
49 20 Z. P. Li, X. R. Duan, C. H. Liu, B. A. Du, *Anal. Biochem.*, 2006, **351**, 18.  
50
- 51  
52 21 X. Y. Wang, Y. Xu, X. Xu, K. Hu, M. H. Xiang, L. M. Li, F. Liu, N. Li, *Talanta*,  
53  
54 2010, **82**, 693.  
55
- 56  
57 22 X. L. Zuo, S. P. Song, J. Zhang, D. Pan, L. H. Wang, C. H. Fan, *J. Am. Chem.*  
58  
59 *Soc.*, 2007, **129**, 1042.  
60

- 1  
2  
3  
4 23 D. F. Bibby, A. C. Gill, L. Kirby, C. F. Farquhar, M. E. Bruce, J. A. Garson, *J.*  
5  
6  
7 *Virol. Methods.*, 2008, **151**, 107.  
8
- 9 24 K. Takemura, P. Wang, I. Vorberg, W. Surewicz, S. A. Priola, A. Kanthasamy,  
10  
11 R. Pottathil, S. G. Chen, S. Sreevatsan, *Exp. Biol. Med.*, 2006, **231**, 204.  
12  
13
- 14 25 S. J. Xiao, P. P. Hu, X. D. Wu, Y. L. Zou, L. Q. Chen, L. Peng, J. Ling, S. J.  
15  
16  
17 Zhen, L. Zhan, Y. F. Li, C. Z. Huang, *Anal. Chem.*, 2010, **82**, 9736.  
18  
19
- 20 26 G. Frens, *Nature*, 1973, **241**, 20.  
21  
22
- 23 27 J. J. Storhoff, R. Elghanian, R. C. Mucic, C. A. Mirkin, R. L. Letsinger, *J. Am.*  
24  
25  
26 *Chem. Soc.*, 1998, **120**, 1959.  
27
- 28 28 P. Hazarika, B. Ceyhan, C. M. Niemeyer, *Small*, 2005, **1**, 844.  
29  
30
- 31 29 C. M. Niemeyer, B. Ceyhan, M. Noyong, U. Simon, *Biochem. Biophys. Res.*  
32  
33  
34 *Commun.*, 2003, **311**, 995.  
35
- 36 30 S. L. Yu, L. Jin, M. S. Sy, F. H. Mei, S. L. Kang, G. H. Sun, P. Tien, F. S. Wang,  
37  
38  
39 G. F. Xiao, *Eur. J. Hum. Genet.*, 2004, **12**, 867.  
40  
41
- 42 31 S. M. Yin, Y. Zheng, P. Tien, *Protein Expres. Purif*, 2003, **32**, 104.  
43  
44
- 45 32 R. F. Pasternack, P. J. Collings, *Science*, 1995, **269**, 935.  
46  
47
- 48 33 V.L. Colvin, K.M. Kulinowski, *Proc. Natl. Acad. Sci. U.S.A.*, 2007, **104**,  
49  
50  
51 8679.  
52
- 53 34 S. Linse, C. Cabaleiro-Lago, W.F. Xue, I. Lynch, S. Lindman, E. Thulin, S.E.  
54  
55  
56 Radford, K.A. Dawson, *Proc. Natl. Acad. Sci. U.S.A.*, 2007, **104**, 8691.  
57
- 58 35 C. C. Huang, Y. F. Huang, Z. H. Cao, W. H. Tan, H. T. Chang, *Anal. Chem.*,  
59  
60  
2005, **77**, 5735.

- 1  
2  
3  
4 36 T. Pan, R. L. Li, B. S. Wong, S. C. Kang, J. Ironside, M. S. Sy, *J Clin.*  
5  
6  
7 *Microbiol.*, 2005, **43**, 1118.  
8  
9  
10 37 L. Y. Zhang, H. Z. Zheng, Y. J. Long, C. Z. Huang, J. Y. Hao, D. B. Zhou,  
11  
12 *Talanta*, 2011, **83**, 1716.  
13  
14  
15 38 H. J. Zhang, H. Z. Zheng, Y. J. Long, G. F. Xiao, L. Y. Zhang, Q. L. Wang, M.  
16  
17 Gao, W. J. Bai, *Talanta*, 2012, **89**, 401.  
18  
19  
20 39 P. Brown, L. Cevenakova, H. Diringer, *J. Lab Clin. Med.*, 2001, **137**, 5.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 An aptamer-functionalized gold nanoparticle biosensor for the detection  
5  
6 of prion protein  
7

8 Hai-Jie Zhang<sup>a,b</sup>, Yi-Hui Lu<sup>a</sup>, Yi-Juan Long<sup>a</sup>, Qin-Long Wang<sup>a</sup>, Xiao-Xiao Huang<sup>a</sup>, Rui Zhu<sup>a</sup>,  
9  
10 Xi-Liang Wang<sup>a</sup>, Li-Ping Liang<sup>a</sup>, Ping Teng<sup>a</sup>, Hu-Zhi Zheng<sup>a\*</sup>  
11



The resonance light scattering intensity of gold nanoparticles which modified a prion protein (rPrP) aptamer increased after addition of rPrP.